192 related articles for article (PubMed ID: 8363226)
1. Guanine arabinoside as a bone marrow-purging agent.
Kurtzberg J
Ann N Y Acad Sci; 1993 Jun; 685():225-36. PubMed ID: 8363226
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: application to an in vivo T-leukemia model.
Gravatt LC; Chaffee S; Hebert ME; Halperin EC; Friedman HS; Kurtzberg J
Leukemia; 1993 Aug; 7(8):1261-7. PubMed ID: 8350627
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine.
Hebert ME; Greenberg ML; Chaffee S; Gravatt L; Hershfield MS; Elion GB; Kurtzberg J
Transplantation; 1991 Oct; 52(4):634-40. PubMed ID: 1926342
[TBL] [Abstract][Full Text] [Related]
4. Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells.
Shewach DS; Mitchell BS
Cancer Res; 1989 Dec; 49(23):6498-502. PubMed ID: 2819707
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging.
Gautam SC; Xu YX; Dumaguin M; Janakiraman N; Chapman RA
Bone Marrow Transplant; 2000 Mar; 25(6):639-45. PubMed ID: 10734298
[TBL] [Abstract][Full Text] [Related]
6. Activation of guanine-β-D-arabinofuranoside and deoxyguanosine to triphosphates by a common pathway blocks T lymphoblasts at different checkpoints.
Leanza L; Miazzi C; Ferraro P; Reichard P; Bianchi V
Exp Cell Res; 2010 Dec; 316(20):3443-53. PubMed ID: 20603113
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
[TBL] [Abstract][Full Text] [Related]
8. Differential cytotoxicity of an ether lipid on lymphoma and bone marrow cells and its role in purging malignant lymphoid cells from remission bone marrow contaminated with tumor cells.
Dietzfelbinger HF; Lang A; Oberberg D; Rastetter JW; Berdel WE
Exp Hematol; 1992 Feb; 20(2):178-83. PubMed ID: 1544386
[TBL] [Abstract][Full Text] [Related]
9. Use of etoposide in combination with cyclosporin for purging multidrug-resistant leukemic cells from bone marrow in a mouse model.
Kühl JS; Sikic BI; Blume KG; Chao NJ
Exp Hematol; 1992 Oct; 20(9):1048-54. PubMed ID: 1468539
[TBL] [Abstract][Full Text] [Related]
10. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
Vogler WR; Olson AC; Berdel WE; Okamoto S; Glasser L
Prog Clin Biol Res; 1990; 333():1-18; discussion 19-20. PubMed ID: 2308973
[TBL] [Abstract][Full Text] [Related]
11. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
12. Spermine dialdehyde, a novel ex vivo purging agent for both allogenic and autologous bone marrow transplantations.
Lau C; Wang E; Ishaque A; Jones K; Wong B; Kimsto L; Conant J
Int J Immunopharmacol; 1992 Aug; 14(6):1081-91. PubMed ID: 1428363
[TBL] [Abstract][Full Text] [Related]
13. Autologous bone marrow transplantation in acute leukemia with marrow purged with alkyl-lysophospholipid.
Vogler WR; Berdel WE; Olson AC; Winton EF; Heffner LT; Gordon DS
Blood; 1992 Sep; 80(6):1423-9. PubMed ID: 1520869
[TBL] [Abstract][Full Text] [Related]
14. Dual mechanisms of 9-beta-D-arabinofuranosylguanine resistance in CEM T-lymphoblast leukemia cells.
Curbo S; Zhu C; Johansson M; Balzarini J; Karlsson A
Biochem Biophys Res Commun; 2001 Jul; 285(1):40-5. PubMed ID: 11437369
[TBL] [Abstract][Full Text] [Related]
15. Clinically relevant deoxycytidine levels are high enough to profoundly alter 9-beta-D-arabinofuranosylguanine cytotoxicity for human T-cell acute leukemia cells in vitro.
Cohen JD; Strock DJ; Teik JE; LaGuardia EA; Katz TB
Pediatr Hematol Oncol; 1999; 16(3):239-44. PubMed ID: 10326222
[TBL] [Abstract][Full Text] [Related]
16. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic marrow purging in murine T cell leukemia.
Copelan EA; Johnson SC; Grever MR; Sheridan JF; Tutschka PJ
Blood; 1988 Jun; 71(6):1656-61. PubMed ID: 2836002
[TBL] [Abstract][Full Text] [Related]
18. Nelarabine: a new purine analog in the treatment of hematologic malignancies.
Curbo S; Karlsson A
Rev Recent Clin Trials; 2006 Sep; 1(3):185-92. PubMed ID: 18473971
[TBL] [Abstract][Full Text] [Related]
19. Increased sensitivity of myeloid leukemia cell lines: potential of lovastatin as bone-marrow-purging agent.
Scheffold C; Schöttker B; Lefterova P; Csipai M; Glasmacher A; Huhn D; Neubauer A; Schmidt-Wolf IG
Acta Haematol; 2000; 104(2-3):72-9. PubMed ID: 11154978
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia.
Rowley SD; Jones RJ; Piantadosi S; Braine HG; Colvin OM; Davis J; Saral R; Sharkis S; Wingard J; Yeager AM
Blood; 1989 Jul; 74(1):501-6. PubMed ID: 2665843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
